Various classes of biologics, namely, anti-tumour necrosis factor (TNF) antibodies, anti-integrins, anti-IL-12/23p40, anti-IL23p19 and oral small molecules (JAKi) have been developed in the last two decades and many of them are now assimilated in world-wide inflammatory bowel disease (IBD) practice.7 8. This evidence concerns the gene IL23A and inflammatory bowel disease.